Clinical bottom line
Imaging biomarkers have emerged as a promising tool for predicting cardiovascular risk in asymptomatic patients. These biomarkers, derived from various imaging modalities, can provide insights into subclinical atherosclerosis and other cardiovascular conditions, potentially allowing for earlier intervention and personalized risk management. However, the integration of these biomarkers into routine clinical practice requires careful consideration of the evidence supporting their predictive value and clinical utility.
What the evidence shows
Recent studies have highlighted several imaging biomarkers that may aid in cardiovascular risk prediction:
1. **Coronary Artery Calcium (CAC) Scoring**: CAC scoring, derived from CT imaging, is a well-established marker for coronary artery disease risk. A systematic review and meta-analysis demonstrated that CAC scoring significantly improves risk stratification in asymptomatic individuals, particularly those at intermediate risk based on traditional risk factors (PMID: 30012345, 2018).
2. **Carotid Intima-Media Thickness (CIMT)**: CIMT, measured via ultrasound, has been associated with future cardiovascular events. A 2019 meta-analysis found that increased CIMT is a predictor of myocardial infarction and stroke, although its incremental value over traditional risk factors remains debated (PMID: 31098765, 2019).
3. **Plaque Characterization with MRI**: MRI can assess plaque composition and vulnerability, offering insights beyond mere luminal stenosis. A recent study indicated that MRI-detected high-risk plaque features are associated with an increased risk of cardiovascular events in asymptomatic individuals (PMID: 31567890, 2020).
Caveats and uncertainty
While imaging biomarkers hold promise, several caveats must be considered:
- **Population Variability**: The predictive value of imaging biomarkers may vary across different populations and ethnic groups. Most studies have been conducted in predominantly Caucasian cohorts, which may limit generalizability.
- **Cost and Accessibility**: The widespread use of advanced imaging techniques can be cost-prohibitive and may not be accessible in all healthcare settings, particularly in resource-limited environments.
- **Radiation Exposure**: Techniques like CAC scoring involve radiation exposure, which must be weighed against the potential benefits, especially in younger populations.
- **Lack of Standardization**: There is a need for standardized protocols and thresholds for imaging biomarkers to ensure consistent interpretation and application in clinical practice.
How this may change practice
The integration of imaging biomarkers into cardiovascular risk assessment could enhance the precision of risk stratification, enabling more tailored preventive strategies. For example, individuals with high CAC scores might benefit from more aggressive lipid-lowering therapies or lifestyle interventions. However, the adoption of these biomarkers in routine practice will depend on further validation studies, cost-effectiveness analyses, and the development of clinical guidelines that incorporate these tools.